Viking Therapeutics (VKTX) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
March 14, 2019 7:35 AM EDTMaxim Group analyst Jason McCarthy lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $20.00 (from $28.00) while maintaining a Buy rating following Q4.
Viking reported 4Q18 with a net loss of ($5.6M) and ended the year with $302M in cash on the balance sheet. Over the course of 2018, the NASH space continued to deliver positive data, in... More